Brain Cancer Archives - Cancer Therapy Advisor

It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.

How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials

By

August 7, 2020

It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.

General Oncology

Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19

By

Randi Hernandez

July 24, 2020

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.

New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.

General Oncology

Conflicts of Interest Continue to Plague Oncology Guidelines and Research

By

Agata Boxe

July 15, 2020

New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.

Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.

General Oncology

Why Cancer Centers May Need to Rethink the Hard Sell to Patients

By

Sarah Elizabeth Richards

July 14, 2020

Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.

Brain Cancer

FDA Grants Orphan Drug Status to Berubicin for Malignant Gliomas

By

Brian Park, PharmD

June 16, 2020

he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.

A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.

General Oncology

Has the Time for At-Home Cancer Care Finally Come?

By

Sarah Elizabeth Richards

June 10, 2020

A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.

Phase 2 studies show in vitro effectiveness in various glioblastoma multiforme cell lines.

Brain Cancer

CheckMate 143: Nivolumab Produces Disappointing Results in Patients with Recurrent Glioblastoma

By

John Schieszer

June 4, 2020

Nivolumab monotherapy fails to improve OS compared to bevacizumab in the treatment of recurrent glioblastoma.

Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers in adoption of genetic testing

General Oncology

Genomics Industry Tries New Strategies to Engage Community Oncologists

By

Sarah Elizabeth Richards

May 21, 2020

Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.

The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.

General Oncology

A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials

By

Caroline Seydel

May 13, 2020

The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.

Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diag

Brain Cancer

Short Treatment Delays May Not Hamper Survival in Glioblastoma

By

Christina Bennett, MS

May 7, 2020

For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.